Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
$13.77
-2.0%		$19.58
$89.95
▼
$99.05
$399.12M0.9553,591 shs1.07 million shs
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$1.89
+0.5%		$1.99
$1.60
▼
$4.94
$108.01M3.32541,168 shs472,186 shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$4.54
+11.8%		$3.61
$2.74
▼
$8.59
$388.34M1.642.04 million shs2.27 million shs
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$17.42
$17.42
$14.50
▼
$19.92
$424.04M1.1518,480 shsN/A
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-1.99%-6.52%-34.49%-35.98%+59.56%
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
+0.53%+0.53%-11.68%-5.97%-49.19%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
+11.82%+8.87%+40.56%-24.21%-41.27%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.00%0.00%0.00%0.00%-6.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
$13.77
-2.0%		$19.58
$89.95
▼
$99.05
$399.12M0.9553,591 shs1.07 million shs
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$1.89
+0.5%		$1.99
$1.60
▼
$4.94
$108.01M3.32541,168 shs472,186 shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$4.54
+11.8%		$3.61
$2.74
▼
$8.59
$388.34M1.642.04 million shs2.27 million shs
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$17.42
$17.42
$14.50
▼
$19.92
$424.04M1.1518,480 shsN/A
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-1.99%-6.52%-34.49%-35.98%+59.56%
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
+0.53%+0.53%-11.68%-5.97%-49.19%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
+11.82%+8.87%+40.56%-24.21%-41.27%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.00%0.00%0.00%0.00%-6.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
0.00
N/AN/AN/A
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
2.64
Moderate Buy$10.25442.33% Upside
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
1.75
Reduce$3.93-13.36% Downside
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest BDTX, PRTC, MYGN, and AVTE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$4.00 ➝ $8.00
9/9/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$6.00 ➝ $3.60
9/1/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Underweight$5.45 ➝ $2.00
8/18/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Stephens logo
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$5.00 ➝ $3.00
8/6/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/6/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/6/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/4/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
8/3/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$5.50 ➝ $3.00
7/31/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetHold$6.00 ➝ $4.00
7/30/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/A$3.96 per shareN/A
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/AN/A$0.53 per share3.57$1.97 per shareN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$824.50M0.53$4.20 per share1.08$3.95 per share1.15
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$4.66M91.01N/AN/A$12.65 per share1.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/A
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$22.37M-$0.75N/AN/AN/AN/A-32.10%-25.21%11/5/2026 (Estimated)
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$365.90M-$1.19N/AN/AN/A-13.96%-16.09%-8.10%11/2/2026 (Estimated)
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
-$109.74MN/AN/AN/AN/AN/AN/AN/AN/A

Latest BDTX, PRTC, MYGN, and AVTE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-$0.1954-$0.17+$0.0254-$0.17$5.56 millionN/A
7/30/2026Q2 2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$0.0579-$0.25-$0.1921-$0.46$206.03 million$190.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/AN/A
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/AN/AN/AN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
N/AN/AN/AN/AN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
8.78
8.78
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/A
7.28
7.28
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.40
2.21
1.98
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/A
6.59
6.59

Institutional Ownership

CompanyInstitutional Ownership
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
95.47%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
99.02%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.04%

Insider Ownership

CompanyInsider Ownership
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
24.90%
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
9.29%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
1.90%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
2028.99 million21.69 millionOptionable
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
2157.45 million52.12 millionOptionable
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2,70095.65 million93.83 millionOptionable
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
10024.34 million23.05 millionNot Optionable

Recent News About These Companies

Tang Capital Management Boosts PureTech Health (PRTC) Stake to 7.08% After Recent Share Purchase
September 27, 2026  |  kalkinemedia.comK
PureTech Health tries a lower-risk model
September 22, 2026  |  investorschronicle.co.ukhttps://www.investorschronicle.co.uk/content/b84f10c7-b674-47e5-a4e7-12c7eddbf78c
PureTech Health H1 Earnings Call Highlights
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/transcript-puretech-health-h1-earnings-call-highlights-2026-09-22/
PureTech Health (PRTC) Rises After FDA Fast Track for Blood-Cancer Drug LYT-200
September 21, 2026  |  asktraders.comA
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R ...
September 21, 2026  |  streetinsider.comhttps://www.streetinsider.com/Business+Wire/PureTech+Announces+Successful+End-of-Phase+1+Meeting+with+U.S.+Food+and+Drug+Administration+%28FDA%29+and+Receipt+of+Fast+Track+Designation+for+LYT-200+in+RelapsedRefractory+%28RR%29+High-Risk+Myelodysplast/27082098.html
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis ...
July 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/puretech-founded-entity-celea-therapeutics-060000287.html
PureTech Subsidiary Celea Begins Phase 3 IPF Study Comparing Deupirfenidone With Standard Therapy (PRTC)
July 13, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/puretech-subsidiary-celea-begins-phase-071627519.html
PureTech entity Celea raises $180 million to move lung disease drug into late stage trial
July 2, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/puretech-entity-celea-raises-180-million-move-lung-disease-drug-into-late-stage-2026-07-02/
PureTech Health plc American Depositary Shares (PRTC) Real-Time
July 1, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/prtc/real-time
2 UK shares tipped to more than double my money in 2026!
June 20, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/2-uk-shares-tipped-more-063100674.html
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
June 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/puretech-founded-entity-seaport-therapeutics-060000179.html
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
May 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260513421721/en/puretech-to-showcase-deupirfenidone-program-at-the-american-thoracic-society-international-conference/
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
May 1, 2026  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1091582?snapi
PureTech Announces Annual Results for Year Ended December 31, 2025
April 29, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260428142968/en/puretech-announces-annual-results-for-year-ended-december-31-2025/
PureTech Health: Notice of Results
April 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260412617965/en/puretech-health-notice-of-results/
PureTech Gains on Results
April 2, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23028/PureTech-Gains-on-Results
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
April 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260401875786/en/puretech-announces-publication-of-phase-2b-elevate-ipf-trial-results-in-the-american-journal-of-respiratory-and-critical-care-medicine/
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
March 25, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260325523679/en/puretech-founded-entity-seaport-therapeutics-announces-publication-in-science-translational-medicine-featuring-glyphallo%e2%84%a2-spt-300-as-the-first-triglyceride-mimetic-prodrug-to-achieve-therapeutically-relevant-drug-levels-in-humans/
PureTech to Present at the Leerink Partners Global Healthcare Conference
February 25, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260224469853/en/puretech-to-present-at-the-leerink-partners-global-healthcare-conference/
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
February 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260219184180/en/puretech-announces-orphan-drug-designations-granted-by-the-u.s.-food-and-drug-administration-and-european-commission-for-deupirfenidone-lyt-100-in-idiopathic-pulmonary-fibrosis/
PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
January 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4859997-puretech-health-plc-prtc-presents-at-44th-annual-j-p-morgan-healthcare-conference-transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aerovate Therapeutics stock logo

Aerovate Therapeutics NASDAQ:AVTE

$13.77 -0.28 (-1.99%)
As of 10/1/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Black Diamond Therapeutics stock logo

Black Diamond Therapeutics NASDAQ:BDTX

$1.89 +0.01 (+0.53%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$1.88 -0.01 (-0.74%)
As of 10/2/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Myriad Genetics stock logo

Myriad Genetics NASDAQ:MYGN

$4.54 +0.48 (+11.82%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$4.49 -0.05 (-1.15%)
As of 10/2/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$17.42 0.00 (0.00%)
As of 10/1/2026

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas